{"id":70799,"date":"2026-05-12T11:37:16","date_gmt":"2026-05-12T11:37:16","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70799"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"glow","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/glow\/","title":{"rendered":"GLOW Blend (BPC-157 10 mg + GHK-Cu 50 mg + TB-500 10 mg)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u00e9ponse rapide \u2014 Qu'est-ce que GLOW ?<\/h3>\n<p style=\"margin: 0;\"><strong>GLOW<\/strong> est un m\u00e9lange co-formul\u00e9 de trois peptides combinant <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a> 10\u00a0mg, <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a> 50\u00a0mg, et <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a> 10\u00a0mg in a single lyophilized vial. The combination covers three complementary regenerative mechanisms in one administration: BPC-157&#8217;s local angiogenic and growth-factor signalling, GHK-Cu&#8217;s copper-mediated dermal remodelling, and TB-500&#8217;s systemic G-actin-binding tissue migration. Each vial contains 70\u00a0mg of total peptide for clinical studies use only.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Composition<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">BPC-157 10\u00a0mg + GHK-Cu 50\u00a0mg + TB-500 10\u00a0mg par flacon (ratio massique 1:5:1, co-formul\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Masse totale de peptide par flacon<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">70\u00a0mg de masse peptidique totale<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ros CAS des composants<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">137525-51-0 (BPC-157) \/ 49557-75-7 (GHK-Cu) \/ 77591-33-4 (TB-500 \/ thymosine b\u00eata-4)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Profil de m\u00e9canisme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Angiogen\u00e8se m\u00e9di\u00e9e par le VEGF (BPC-157) + remodelage dermique m\u00e9di\u00e9 par le cuivre (GHK-Cu) + migration tissulaire syst\u00e9mique li\u00e9e \u00e0 la G-actine (TB-500) \u2014 trois voies r\u00e9g\u00e9n\u00e9ratives compl\u00e9mentaires<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Poudre co-formul\u00e9e lyophilis\u00e9e (teinte bleu clair due au Cu li\u00e9)<sup>2+<\/sup>)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599 % (chaque composant v\u00e9rifi\u00e9 par HPLC, COA sur demande)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C (r\u00e9frig\u00e9rateur) pour le stock de travail ; \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Reconstitu\u00e9 : 2\u20138 \u00b0C, \u00e0 utiliser dans ~30 jours. Prot\u00e9ger de la lumi\u00e8re. Ne pas congeler-d\u00e9congeler la solution reconstitu\u00e9e.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Eau bact\u00e9riostatique (recommand\u00e9e). Les trois peptides se reconstituent simultan\u00e9ment \u00e0 partir du m\u00eame flacon ; la solution reconstitu\u00e9e doit conserver une l\u00e9g\u00e8re teinte bleue due au Cu li\u00e9<sup>2+<\/sup> du GHK-Cu.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que GLOW ?<\/h2>\n<p><strong>GLOW<\/strong> is a pharmaceutical-grade co-formulated three-peptide blend that combines <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a> (Compos\u00e9 de protection corporelle 157), <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a> (Complexe de cuivre(II) glycyl-histidyl-lysine), et <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a> (Thymosin Beta-4 fragment) in a single lyophilized vial at a 1:5:1 mass ratio \u2014 10\u00a0mg BPC-157, 50\u00a0mg GHK-Cu, and 10\u00a0mg TB-500 per vial, for a total of 70\u00a0mg peptide mass. The three peptides represent three of the most cited regenerative-compounds in the published literature, each acting on a different molecular axis: BPC-157 on local angiogenesis and growth-factor signalling, GHK-Cu on copper-mediated dermal remodelling and antioxidant signalling, and TB-500 on systemic G-actin-binding and cell migration. The strategic rationale for the GLOW blend is <strong>m\u00e9canismes compl\u00e9mentaires et non redondants<\/strong> across three regenerative axes. Each component peptide has a distinct molecular target and tissue-distribution pattern, so co-administration covers a broader range of studies endpoints than any single component alone. The blend is intended for studies that benefits from simultaneous activation of all three pathways \u2014 a use case distinct from studies designs that require independent dosing of each component peptide. For studies that needs <strong>une administration ind\u00e9pendante<\/strong> de chaque peptide (dosages diff\u00e9rents, sch\u00e9mas posologiques diff\u00e9rents, formulations de v\u00e9hicule diff\u00e9rentes), les composants sont \u00e9galement disponibles en flacons individuels : <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a>, et <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a>. Un pack s\u00e9par\u00e9 de trois flacons \u2014 le <a href=\"https:\/\/medsbase.com\/fr\/peptide-healing-stack\/\">Peptide Healing Stack<\/a> (BPC-157 + TB-500 + bacteriostatic water shipped together as three separate vials) \u2014 provides another alternative for studies requiring per-component dose-flexibility. The GLOW co-formulation is specifically for studies at the fixed 1:5:1 mass ratio with single-vial reconstitution. GLOW is supplied as a high-purity lyophilized blend for reconstitution with bacteriostatic water. The reconstituted solution retains a faint blue tint from the bound Cu<sup>2+<\/sup> du composant GHK-Cu \u2014 un indicateur qualitatif utile confirmant que la coordination du cuivre est rest\u00e9e intacte pendant la lyophilisation et la reconstitution. GLOW n'est <strong>non approuv\u00e9<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as a combination or as any of its component peptides. <\/p>\n<h2>M\u00e9canisme d'action \u2014 Trois voies r\u00e9g\u00e9n\u00e9ratives compl\u00e9mentaires<\/h2>\n<p>Ce qui rend la co-formulation GLOW pharmacologiquement distinctive est son <strong>profil m\u00e9canistique tri-axial<\/strong> \u2014 each component activates a fundamentally different regenerative pathway, and the three are non-overlapping at the molecular level. Published studies on each component has established the mechanism in detail; the combination simply delivers all three in a single administration:<\/p>\n<ul>\n<li><strong>BPC-157 (10 mg) \u2014 signalisation VEGF\/NO\/r\u00e9cepteur GH pour la r\u00e9paration tissulaire locale<\/strong> \u2014 The 15-amino-acid pentadecapeptide derived from gastric juice upregulates VEGFR2 (driving new capillary formation at injury sites), enhances endothelial nitric oxide synthase activity (protecting vascular endothelium), and increases growth-hormone receptor expression on fibroblasts and tenocytes (driving collagen synthesis). Most-cited signal: tendon, ligament, gut barrier, and skeletal muscle recovery. Acts more locally than systemic at the injection site.<\/li>\n<li><strong>GHK-Cu (50 mg) \u2014 remodelage dermique et signalisation antioxydante m\u00e9di\u00e9e par le cuivre<\/strong> \u2014 L'ion Cu<sup>2+<\/sup>-coordinated tripeptide delivers copper as an enzyme cofactor for lysyl oxidase (collagen\/elastin cross-linking) and superoxide dismutase (oxidative-stress buffering) while signalling on dermal fibroblasts and keratinocytes. Most-cited signal: skin remodelling, wound healing, anti-aging in connective-tissue studies, hair follicle support, copper-axis pharmacology. Higher mass loading (50\u00a0mg in the blend) reflects the larger doses typical of copper-peptide studies vs the microgram-range doses of the other two components.<\/li>\n<li><strong>TB-500 (10 mg) \u2014 s\u00e9questration de G-actine et migration cellulaire syst\u00e9mique<\/strong> \u2014 The 43-amino-acid thymic peptide is the canonical systemic regenerative compound, binding monomeric G-actin and modulating actin dynamics to drive cell migration, particularly at injury sites. Most-cited signal: systemic muscle and cardiac recovery, vascular repair, and broad systemic distribution that complements BPC-157&#8217;s more localised action. Acts as the &#8220;systemic arm&#8221; to BPC-157&#8217;s &#8220;local arm&#8221;.<\/li>\n<\/ul>\n<p>Les trois voies sont <strong>m\u00e9canistiquement compl\u00e9mentaires<\/strong>, not redundant: BPC-157 acts locally on the injury site, TB-500 distributes systemically and supports cell migration globally, and GHK-Cu provides copper-cofactor delivery and dermal-tissue-specific signalling. Co-administering the three in study models covers angiogenesis (BPC-157), systemic recovery (TB-500), and dermal-tissue remodelling (GHK-Cu) simultaneously \u2014 a broader studies endpoint coverage than any single component alone. All three peptides have well-tolerated profiles in published preclinical studies, and combination protocols are described in some published studies models of multi-axis tissue regeneration. <\/p>\n<h2>Published Evidence<\/h2>\n<p>GLOW co-formulation is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Multi-axis tissue regeneration<\/strong> \u2014 preclinical models combining systemic and local regenerative endpoints; angiogenesis + cell migration + dermal remodelling in single studies designs<\/li>\n<li><strong>Wound healing studies<\/strong> \u2014 mod\u00e8les de plaies cutan\u00e9es (pleine \u00e9paisseur, \u00e9paisseur partielle, br\u00fblures), cin\u00e9tique de contraction des plaies, formation de tissu de granulation, caract\u00e9risation du tissu cicatriciel ; une des approches multi-axes les plus compl\u00e8tes<\/li>\n<li><strong>R\u00e9cup\u00e9ration des tendons, ligaments et tissus mous<\/strong> \u2014 rodent Achilles transection models, medial-collateral-ligament rupture studies; published BPC-157 + TB-500 literature is extensive, with the GHK-Cu addition providing copper-cofactor support for collagen cross-linking<\/li>\n<li><strong>Skin remodelling and dermal studies<\/strong> \u2014 collagen and elastin synthesis, dermal-fibroblast proliferation, photo-aging studies; the GHK-Cu component dominates this studies domain<\/li>\n<li><strong>Comparative co-formulation studies<\/strong> \u2014 comparaison directe avec des formulations autonomes <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a>, et <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a> bras ; dissection des effets additifs versus synergiques \u00e0 travers la combinaison \u00e0 trois axes<\/li>\n<li><strong>Vascular and cardiac recovery<\/strong> \u2014 le signal angiog\u00e9nique (BPC-157) et migratoire (TB-500) combin\u00e9 est bien adapt\u00e9 aux mod\u00e8les de r\u00e9cup\u00e9ration vasculaire et d'isch\u00e9mie cardiaque<\/li>\n<li><strong>Anti-aging and longevity studies<\/strong> \u2014 published work on copper-peptide effects in dermal and connective-tissue aging, particularly relevant for the GHK-Cu component; combined with BPC-157 + TB-500 for broader tissue-aging studies designs<\/li>\n<li><strong>Inflammation and oxidative-stress studies<\/strong> \u2014 copper&#8217;s role as cofactor for superoxide dismutase plus the BPC-157 and TB-500 inflammation-modulating effects provide multi-axis anti-inflammatory studies coverage.<\/li>\n<\/ul>\n<p>Pour un contexte plus large, consultez nos <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a>, et <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a> pages produit pour la pharmacologie au niveau des composants, le <a href=\"https:\/\/medsbase.com\/fr\/peptide-healing-stack\/\">Peptide Healing Stack<\/a> pour l'alternative en bundle de trois flacons s\u00e9par\u00e9s (BPC-157 + TB-500 + eau bact\u00e9riostatique), et le peptide de cuivre apparent\u00e9 <a href=\"https:\/\/medsbase.com\/fr\/ahk-cu\/\">AHK-Cu<\/a> for hair-axis studies. Browse the full <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">catalogue de peptides<\/a> pour les compos\u00e9s associ\u00e9s. <\/p>\n<h2>Configurations disponibles<\/h2>\n<p>MedsBase propose le m\u00e9lange GLOW en une seule co-formulation : <strong>10 mg de BPC-157 + 50 mg de GHK-Cu + 10 mg de TB-500 par flacon<\/strong> (ratio massique 1:5:1, 70 mg de peptides au total). Le flacon est disponible en packs de 10 ou 20 flacons avec un guide complet de reconstitution :<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Composition du flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg de BPC-157 + 50 mg de GHK-Cu + 10 mg de TB-500<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard tri-axis regenerative-studies blend \u2014 angiogenesis + dermal remodelling + systemic cell migration in single administration<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 ou 20 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three components are supplied at \u226599% HPLC purity (each verified individually) and pre-mixed in the same lyophilized vial. Because the three peptides have different dose ranges and different roles in the blend, the 1:5:1 mass ratio is fixed at manufacture. Users requiring different ratios should use the stand-alone <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a>, et <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a> vials instead. Compared with purchasing the three components separately, the GLOW co-formulation offers a meaningful cost saving and the practical convenience of single-vial reconstitution at the fixed studies ratio. <\/p>\n<h2>Comparaison \u2014 GLOW Blend vs Peptide Healing Stack<\/h2>\n<p>MedsBase carries two multi-peptide studies products that combine the same broader healing-peptide pharmacology in different packaging formats. The choice between them depends on studies design requirements:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">M\u00e9lange GLOW<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\"><a href=\"https:\/\/medsbase.com\/fr\/peptide-healing-stack\/\">Peptide Healing Stack<\/a><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Format d'emballage<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Flacon unique, co-formul\u00e9<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Trois flacons s\u00e9par\u00e9s exp\u00e9di\u00e9s ensemble<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Composition<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">BPC-157 10\u00a0mg + GHK-Cu 50\u00a0mg + TB-500 10\u00a0mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">BPC-157 5\u00a0mg + TB-500 5\u00a0mg + Eau bact\u00e9riostatique<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Nombre de composants<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Trois peptides (ajoute un peptide de cuivre)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Deux peptides + diluant (sans peptide de cuivre)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Flexibilit\u00e9 de dosage<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Rapport massique fixe de 1:5:1 par flacon<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Ind\u00e9pendance de dosage par composant<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Reconstitution<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u00c9v\u00e9nement de reconstitution unique<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Reconstitution par flacon<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Cas d'utilisation<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Convenience + fixed-ratio studies; broader 3-axis coverage including dermal remodelling<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Dose-flexible studies; classic 2-axis healing focus (BPC + TB only)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Studies designs that require flexible per-component dosing or that don&#8217;t need the copper-peptide arm should use the <a href=\"https:\/\/medsbase.com\/fr\/peptide-healing-stack\/\">Peptide Healing Stack<\/a>. Studies designs that benefit from the broader three-axis coverage (including dermal-tissue remodelling) and that are comfortable with the fixed 1:5:1 mass ratio should use the GLOW blend. Both options are pre-curated for the most-cited healing-peptide studies pharmacology \u2014 the difference is packaging format and component breadth. <\/p>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> conserver les flacons lyophilis\u00e9s au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C dans leur emballage d'origine pour un stock de travail \u00e0 court terme. Pour un stockage \u00e0 long terme non ouvert, congeler \u00e0 \u221220 \u00b0C. La co-formulation lyophilis\u00e9e GLOW est stable sous r\u00e9frig\u00e9ration jusqu'\u00e0 24 mois et \u00e0 \u221220 \u00b0C jusqu'\u00e0 36 mois. Les trois peptides composants ont des profils de stabilit\u00e9 bien assortis \u00e0 l'\u00e9tat lyophilis\u00e9. \u00c9viter les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation sur la poudre lyophilis\u00e9e. <strong>Proc\u00e9dure de reconstitution :<\/strong> injecter de l'eau bact\u00e9riostatique le long de la paroi du flacon (pas directement sur le g\u00e2teau lyophilis\u00e9). Comme le flacon contient 70 mg de masse peptidique totale, une reconstitution de 2,0 mL donne une concentration de travail totale en peptides de 35 mg\/mL \u2014 \u00e9quivalente \u00e0 5 mg\/mL de BPC-157, 25 mg\/mL de GHK-Cu et 5 mg\/mL de TB-500. Agiter doucement \u2014 ne pas <strong>re\u00e7oit pas<\/strong> secouer \u2014 et laisser 2 \u00e0 5 minutes pour une dissolution compl\u00e8te. Une solution correctement reconstitu\u00e9e doit \u00eatre claire avec une <strong>teinte bleut\u00e9e l\u00e9g\u00e8re<\/strong> provenant du Cu li\u00e9<sup>2+<\/sup> du composant GHK-Cu \u2014 la couleur est un indicateur qualitatif utile que la coordination du cuivre est rest\u00e9e intacte pendant la lyophilisation et la reconstitution. Une opacit\u00e9, un pr\u00e9cipit\u00e9 ou une absence de teinte bleut\u00e9e indique un probl\u00e8me ; jeter et recommencer. <strong>Apr\u00e8s reconstitution :<\/strong> conserver au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C et utiliser dans les 30 jours pour une stabilit\u00e9 optimale des trois composants. Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation d\u00e9gradent l'int\u00e9grit\u00e9 des peptides et peuvent affecter la coordination du cuivre. Prot\u00e9ger de la lumi\u00e8re directe \u00e0 tout moment. Jeter tout flacon pr\u00e9sentant une opacit\u00e9, un pr\u00e9cipit\u00e9 ou une d\u00e9coloration au-del\u00e0 de la teinte bleut\u00e9e l\u00e9g\u00e8re attendue. <\/p>\n<h2 id=\"faqs\">Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>What is GLOW used for in studies?<\/h3>\n<p>GLOW is used in studies investigating multi-axis tissue regeneration \u2014 specifically protocols that benefit from simultaneous activation of three complementary regenerative pathways (BPC-157 angiogenesis + GHK-Cu dermal remodelling + TB-500 systemic cell migration) in a single administration. Common contexts include wound healing models, tendon and soft-tissue recovery, skin remodelling, vascular repair, anti-aging connective-tissue studies, and comparative co-formulation pharmacology. The pharmaceutical-grade GLOW sold here is <strong>re\u00e7oit pas<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>Que contient un flacon de GLOW ?<\/h3>\n<p>Chaque flacon contient <strong>10 mg de BPC-157, 50 mg de GHK-Cu et 10 mg de TB-500<\/strong>, co-formulated and lyophilized together as a single powder. Total peptide mass per vial: 70\u00a0mg. The 1:5:1 mass ratio reflects the different studies-relevant dose ranges of the three components (BPC-157 and TB-500 are used in microgram-to-low-milligram doses; GHK-Cu is used in low-to-mid-milligram doses). All three peptides reconstitute simultaneously when bacteriostatic water is added. <\/p>\n<h3>En quoi GLOW diff\u00e8re-t-il du Peptide Healing Stack ?<\/h3>\n<p>Les deux produits combinent des peptides de gu\u00e9rison apparent\u00e9s mais dans des formats d'emballage diff\u00e9rents. <strong>GLOW<\/strong> est un flacon unique contenant trois peptides (BPC-157 + GHK-Cu + TB-500) co-formul\u00e9s ensemble dans un ratio fixe de 1:5:1. Le <a href=\"https:\/\/medsbase.com\/fr\/peptide-healing-stack\/\">Peptide Healing Stack<\/a> is three separate vials (BPC-157 + TB-500 + bacteriostatic water) shipped in one parcel. GLOW adds the copper-peptide arm and consolidates reconstitution; the Peptide Healing Stack offers per-component dose independence without the copper-peptide component. Choose based on whether your studies needs the dermal-remodelling axis (GLOW) or per-component dose flexibility (Peptide Healing Stack). <\/p>\n<h3>En quoi GLOW diff\u00e8re-t-il des peptides composants individuels ?<\/h3>\n<p>Les composants sont \u00e9galement disponibles sous forme de produits autonomes : <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a>, <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a>, et <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a>. Les flacons autonomes permettent un contr\u00f4le de dose par composant, des calendriers diff\u00e9rents par peptide et des formulations de v\u00e9hicule diff\u00e9rentes par peptide. La co-formulation GLOW fixe le ratio de dose \u00e0 1:5:1 en masse mais offre une commodit\u00e9 (reconstitution unique, injection unique) et des \u00e9conomies de co\u00fbt modestes par rapport \u00e0 l'achat des trois composants s\u00e9par\u00e9ment. <\/p>\n<h3>What is the typical GLOW dose?<\/h3>\n<p>Dose depends on the studies endpoint. Conservative protocols use 0.04\u00a0mL of a 35\u00a0mg\/mL reconstituted solution (~200\u00a0mcg BPC-157 + 1\u00a0mg GHK-Cu + 200\u00a0mcg TB-500 per administration) several times weekly. Higher-dose protocols scale up proportionally within the fixed 1:5:1 ratio. Users requiring different ratios should use the stand-alone components rather than the blend. <\/p>\n<h3>GLOW est-il approuv\u00e9 par la FDA ?<\/h3>\n<p>No. GLOW is not approved by the FDA, EMA, MHRA, or any other major regulator as a combination product. None of the three individual components (BPC-157, GHK-Cu, TB-500) have FDA approval for human therapeutic use either. GHK-Cu is incorporated into some cosmetic products under cosmetic-regulation frameworks, but none of the three peptides is approved as a drug. <\/p>\n<h3>Pourquoi la solution GLOW a-t-elle une teinte bleue ?<\/h3>\n<p>La l\u00e9g\u00e8re teinte bleue provient du Cu li\u00e9<sup>2+<\/sup> du composant GHK-Cu \u2014 sp\u00e9cifiquement des transitions \u00e9lectroniques d-d du cuivre dans l'environnement de coordination plan-carr\u00e9 cr\u00e9\u00e9 par le tripeptide Gly-His-Lys. La couleur est un indicateur qualitatif utile de la coordination intacte du cuivre : une solution GLOW correctement reconstitu\u00e9e devrait pr\u00e9senter une l\u00e9g\u00e8re teinte bleue visible ; une solution incolore ou p\u00e2le sugg\u00e9rerait une perte de cuivre ou une d\u00e9gradation du composant GHK-Cu. Les deux autres peptides (BPC-157, TB-500) ne contribuent \u00e0 aucune couleur. <\/p>\n<h3>Comment GLOW doit-il \u00eatre stock\u00e9 ?<\/h3>\n<p>Flacons lyophilis\u00e9s : r\u00e9frig\u00e9r\u00e9s \u00e0 2\u20138 \u00b0C pour le stock de travail \u00e0 court terme, ou \u00e0 \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Solution reconstitu\u00e9e : r\u00e9frig\u00e9r\u00e9e \u00e0 2\u20138 \u00b0C, \u00e0 utiliser dans les 30 jours. Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de gel-d\u00e9gel d\u00e9gradent l'int\u00e9grit\u00e9 des peptides et pourraient affecter de mani\u00e8re disproportionn\u00e9e soit la coordination du cuivre, soit la stabilit\u00e9 de la structure peptidique. Prot\u00e9ger de la lumi\u00e8re directe en permanence. <\/p>\n<h3>Comment reconstituer GLOW ?<\/h3>\n<p>Suivez la proc\u00e9dure de reconstitution ci-dessus. Ajoutez de l'eau bact\u00e9riostatique le long de la paroi du flacon (pas directement sur la poudre lyophilis\u00e9e), agitez doucement et laissez reposer 2 \u00e0 5 minutes pour une dissolution compl\u00e8te. Ne <strong>re\u00e7oit pas<\/strong> Agiter le flacon. Les trois peptides se reconstituent simultan\u00e9ment \u00e0 partir du m\u00eame flacon. Une solution correctement reconstitu\u00e9e est claire avec une l\u00e9g\u00e8re teinte bleue. Pour un flacon + 2,0 mL de diluant, la concentration de travail est de 5 mg\/mL de BPC-157, 25 mg\/mL de GHK-Cu et 5 mg\/mL de TB-500. <\/p>\n<h3>Quelles configurations MedsBase propose-t-elle en stock ?<\/h3>\n<p>MedsBase propose GLOW en une seule co-formulation : 10 mg de BPC-157 + 50 mg de GHK-Cu + 10 mg de TB-500 par flacon (70 mg de peptide total, ratio massique 1:5:1, lyophilis\u00e9). Le flacon est disponible en tailles de pack de 10 ou 20 flacons. Chaque composant est v\u00e9rifi\u00e9 individuellement \u00e0 une puret\u00e9 HPLC \u226599 % avec un certificat d'analyse disponible sur demande. <\/p>\n<h3>Puis-je acheter les composants de GLOW s\u00e9par\u00e9ment ?<\/h3>\n<p>Oui \u2014 MedsBase propose les trois peptides composants en tant que produits individuels : <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a> en flacons de 2\/5\/10 mg, <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a>, et <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a> in 2\/5\/10\u00a0mg vials. Separate vials are useful if protocols require dose ratios other than the fixed 1:5:1 GLOW ratio, or if users want different scheduling per peptide. The co-formulated GLOW blend offers convenience and cost savings for studies at the 1:5:1 ratio. <\/p>\n<h3>Does GLOW cause side reported effects?<\/h3>\n<p>All three component peptides have well-tolerated profiles in published preclinical studies at typical doses. The most consistent finding for the combination is the same as for the individual components: local injection-site reactions, occasional flushing at higher doses, and (rarely) modest skin discolouration at the injection site from copper deposition (from the GHK-Cu component). Systemic adverse effects are uncommon in published preclinical literature for any of the three peptides. <\/p>\n<h3>How long does GLOW take to show effects in preclinical studies?<\/h3>\n<p>Effect onset varies by studies endpoint. Local wound-healing and tissue-recovery effects are typically measurable within 7\u201314 days of regular dosing. Skin-remodelling effects (collagen synthesis, dermal-fibroblast activity) accumulate over 4\u20138 weeks. Systemic regenerative effects mediated by TB-500 develop over similar timescales. The combined three-axis profile produces a broader endpoint coverage than any single component, but the kinetics for each axis follow the timeline of the respective component peptide. <\/p>\n<h3>Puis-je commander GLOW pour une livraison internationale ?<\/h3>\n<p>Oui. MedsBase exp\u00e9die GLOW dans le monde entier depuis notre r\u00e9seau d'exp\u00e9dition d\u00e9di\u00e9 aux peptides. Les commandes de peptides uniquement sont \u00e9ligibles \u00e0 notre service d'exp\u00e9dition de peptides autonome. Toutes les commandes sont exp\u00e9di\u00e9es dans un emballage \u00e0 temp\u00e9rature contr\u00f4l\u00e9e avec un suivi complet et sont couvertes par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\">Politique de R\u00e9exp\u00e9ditions Garanties<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Tissue Regeneration, Wound Healing, and Recovery Studies<\/h2>\n<ul>\n<li><a href=\"\/fr\/bpc-157\/\"><strong>BPC-157<\/strong><\/a> \u2014 Compos\u00e9 de protection corporelle \u2014 le composant angiogen\u00e8se local de GLOW, flacons autonomes<\/li>\n<li><a href=\"\/fr\/ghk-cu\/\"><strong>GHK-Cu<\/strong><\/a> \u2014 Tripeptide de cuivre \u2014 le composant de remodelage dermique de GLOW, flacons autonomes<\/li>\n<li><a href=\"\/fr\/tb-500\/\"><strong>TB-500 (Thymosine B\u00eata-4)<\/strong><\/a> \u2014 Fragment de gu\u00e9rison syst\u00e9mique \u2014 le composant de migration cellulaire syst\u00e9mique de GLOW<\/li>\n<li><a href=\"\/fr\/peptide-healing-stack\/\"><strong>Peptide Healing Stack<\/strong><\/a> \u2014 Lot alternatif de trois flacons (BPC + TB + eau BAC) sans peptide de cuivre<\/li>\n<li><a href=\"\/fr\/ahk-cu\/\"><strong>AHK-Cu<\/strong><\/a> \u2014 Sister copper peptide to GHK-Cu \u2014 hair follicle compound<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Pour en savoir plus<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore the regenerative-peptide studies landscape<\/strong><\/p>\n<p style=\"margin: 0;\">Parcourez toute la <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\"><strong>catalogue de peptides<\/strong><\/a>, avec des compos\u00e9s r\u00e9g\u00e9n\u00e9rateurs connexes incluant <a href=\"https:\/\/medsbase.com\/fr\/bpc-157\/\">BPC-157<\/a> (angiogen\u00e8se locale), <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a> (migration cellulaire syst\u00e9mique), <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">GHK-Cu<\/a> (remodelage dermique), et l'alternative <a href=\"https:\/\/medsbase.com\/fr\/peptide-healing-stack\/\">Peptide Healing Stack<\/a> lot.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 M\u00e9lange r\u00e9g\u00e9n\u00e9ratif co-formul\u00e9 \u00e0 trois peptides<br \/>\n\u2705 BPC-157 (10mg) + GHK-Cu (50mg) + TB-500 (10mg)<br \/>\n\u2705 Angiogen\u00e8se locale + remodelage dermique + migration cellulaire syst\u00e9mique<br \/>\n\u2705 Un seul flacon, une seule reconstitution<br \/>\n\u2705 70mg de peptide total par flacon<\/p>\n<p><strong>GLOW<\/strong> est un m\u00e9lange de peptides co-formul\u00e9.<\/p>","protected":false},"featured_media":70957,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5440,5449,6291,5441,5442],"class_list":["post-70799","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-bpc-157","product_tag-ghk-cu","product_tag-glow","product_tag-peptide","product_tag-tb-500","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/70799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=70799"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/70957"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=70799"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=70799"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=70799"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=70799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}